Peptide-based Immunotherapy in Lupus: Where Are We Now?

Overview

Journal Rheumatol Immunol Res

Specialty Allergy & Immunology

Date 2023 Oct 2

PMID 37781681

Authors

Ram P Singh

David S Bischoff

Satendra S Singh

Bevra H Hahn

Affiliations

Soon will be listed here.

Abstract

In autoimmune rheumatic diseases, immune hyperactivity and chronic inflammation associate with immune dysregulation and the breakdown of immune self-tolerance. A continued, unresolved imbalance between effector and regulatory immune responses further exacerbates inflammation that ultimately causes tissue and organ damage. Many treatment modalities have been developed to restore the immune tolerance and immmunoregulatory balance in autoimmune rheumatic diseases, including the use of peptide-based therapeutics or the use of nanoparticles-based nanotechnology. This review summarizes the state-of-the-art therapeutic use of peptide-based therapies in autoimmune rheumatic diseases, with a specific focus on lupus.

Citing Articles

Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus.

Karmakar A, Kumar U, Prabhu S, Ravindran V, Nagaraju S, Suryakanth V Clin Exp Med. 2024; 24(1):223.

PMID: 39294397 PMC: 11410857. DOI: 10.1007/s10238-024-01484-z.

References

OConnor R, Li X, Blumerman S, Anderton S, Noelle R, Dalton D . Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR3+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system. J Immunol. 2012; 188(5):2093-101. PMC: 3987917. DOI: 10.4049/jimmunol.1101118. View

Zorzella-Pezavento S, Mimura L, Fraga-Silva T, Watanabe Ishikawa L, Franca T, Sartori A . Experimental Autoimmune Encephalomyelitis Is Successfully Controlled by Epicutaneous Administration of MOG Plus Vitamin D Analog. Front Immunol. 2017; 8:1198. PMC: 5650696. DOI: 10.3389/fimmu.2017.01198. View

Zimmer R, Scherbarth H, Rillo O, Gomez-Reino J, Muller S . Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2012; 72(11):1830-5. PMC: 3812851. DOI: 10.1136/annrheumdis-2012-202460. View

Kang H, Michaels M, Berner B, Datta S . Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol. 2005; 174(6):3247-55. DOI: 10.4049/jimmunol.174.6.3247. View

Zhao Z, Ren J, Dai C, Kannapell C, Wang H, Gaskin F . Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification. Ann Rheum Dis. 2018; 78(3):380-390. PMC: 6377330. DOI: 10.1136/annrheumdis-2018-214125. View

Monneaux F, Muller S . Peptide-based immunotherapy of systemic lupus erythematosus. Autoimmun Rev. 2004; 3(1):16-24. DOI: 10.1016/S1568-9972(03)00061-2. View

DeGiorgio L, Konstantinov K, Lee S, Hardin J, Volpe B, Diamond B . A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med. 2001; 7(11):1189-93. DOI: 10.1038/nm1101-1189. View

Dieker J, Sun Y, Jacobs C, Putterman C, Monestier M, Muller S . Mimotopes for lupus-derived anti-DNA and nucleosome-specific autoantibodies selected from random peptide phage display libraries: facts and follies. J Immunol Methods. 2005; 296(1-2):83-93. DOI: 10.1016/j.jim.2004.10.010. View

Singh R, La Cava A, Wong M, Ebling F, Hahn B . CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol. 2007; 178(12):7649-57. DOI: 10.4049/jimmunol.178.12.7649. View

10.

Zhang L, Bertucci A, Ramsey-Goldman R, Burt R, Datta S . Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J Immunol. 2009; 183(10):6346-58. PMC: 2784684. DOI: 10.4049/jimmunol.0901773. View

11.

Cardiel M, Tumlin J, Furie R, Wallace D, Joh T, Linnik M . Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008; 58(8):2470-80. DOI: 10.1002/art.23673. View

12.

Otomo K, Koga T, Mizui M, Yoshida N, Kriegel C, Bickerton S . Cutting Edge: Nanogel-Based Delivery of an Inhibitor of CaMK4 to CD4+ T Cells Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice. J Immunol. 2015; 195(12):5533-7. PMC: 4670795. DOI: 10.4049/jimmunol.1501603. View

13.

Rosenthal K, Mikecz K, Steiner 3rd H, Glant T, Finnegan A, Carambula R . Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. Expert Rev Vaccines. 2015; 14(6):891-908. PMC: 4786169. DOI: 10.1586/14760584.2015.1026330. View

14.

Slansky J, Nakayama M . Peptide mimotopes alter T cell function in cancer and autoimmunity. Semin Immunol. 2020; 47:101395. PMC: 7160047. DOI: 10.1016/j.smim.2020.101395. View

15.

Yang Y, Santamaria P . Evolution of nanomedicines for the treatment of autoimmune disease: From vehicles for drug delivery to inducers of bystander immunoregulation. Adv Drug Deliv Rev. 2021; 176:113898. DOI: 10.1016/j.addr.2021.113898. View

16.

Wong M, La Cava A . Lupus, the current therapeutic approaches. Drugs Today (Barc). 2011; 47(4):289-302. DOI: 10.1358/dot.2011.47.4.1583186. View

17.

Schall N, Muller S . Resetting the autoreactive immune system with a therapeutic peptide in lupus. Lupus. 2015; 24(4-5):412-8. DOI: 10.1177/0961203314556138. View

18.

Tsokos G . Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110-21. DOI: 10.1056/NEJMra1100359. View

19.

Shapira E, Proscura E, Brodsky B, Wormser U . Novel peptides as potential treatment of systemic lupus erythematosus. Lupus. 2011; 20(5):463-72. DOI: 10.1177/0961203310389484. View

20.

Singh R, Hahn B, La Cava A . Tuning immune suppression in systemic autoimmunity with self-derived peptides. Inflamm Allergy Drug Targets. 2008; 7(4):253-9. DOI: 10.2174/187152808786848423. View